Skip to Content

Xigris

Active Substance: drotrecogin alfa (activated)
Common Name: drotrecogin alfa (activated)
ATC Code: B01AD10
Marketing Authorisation Holder: Eli Lilly Nederland B.V.
Active Substance: drotrecogin alfa (activated)
Status: Withdrawn
Authorisation Date: 2002-08-22
Therapeutic Area: Sepsis Multiple Organ Failure
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. The use of Xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

The marketing authorisation for Xigris has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide